Lu Xu
Shanghai, 200025, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
A phosphoglycerate mutase 1 allosteric inhibitor restrains TAM-mediated colon cancer progression.
Journal: Acta pharmaceutica Sinica. B
Published: March 17, 2024
Valproic acid increased the efficacy of EGFR TKIs on EGFR/TP53 co-mutated lung cancers and downregulated mutant-p53 levels.
Journal: Molecular carcinogenesis
Published: July 03, 2023
Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review.
Journal: Translational cancer research
Published: June 02, 2023
A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: December 20, 2022
TGFβ1/integrin β3 positive feedback loop contributes to acquired EGFR TKI resistance in EGFR-mutant lung cancer.
Journal: Journal of drug targeting
Published: October 11, 2022
Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma.
Journal: Cancer research
Published: November 28, 2021
Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer.
Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer.
Journal: Molecular cancer therapeutics
Published: February 20, 2019
Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Journal: Oncogene
Published: January 22, 2018
Last Updated: 09/26/2026